AICAr to SAICAr ratio can serve as additional marker of AICAr use

Publications: Contribution to journalJournal articlesResearchpeer-review

Authors

Research units

Details

AICAr (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, commonly referred to as AICAR) is an adenosine monophosphate-activated protein kinase agonist previously investigated for its therapeutic potential which has been shown to improve exercise performance in laboratory animals. For this reason, the World Anti-Doping Agency prohibits the use of AICAr in sports. AICAr can easily be detected by means of liquid chromatography–mass spectrometry, but being an endogenous metabolite, it cannot be discriminated from AICAr of a non-natural origin. Population-based concentration thresholds have been suggested as a means to identify suspicious samples that would require further analysis by carbon isotope ratio mass spectrometry (CIR); however, it remains at the discretion of the laboratory how to apply them. Here, the urinary ratio of AICAr to SAICA-riboside (SAICAr) that is a closely related purine metabolite was investigated. In an athlete population of 5517 samples, this ratio was relatively narrowly distributed with median values and 99th percentiles of 3.3 and 9.3, and 4.2 and 14 in male and female athletes, respectively. Analysis of urine samples obtained from an AICAr administration study demonstrated that the AICAr/SAICAr ratio can serve in addition to AICAr concentration as a valuable diagnostic trigger for follow-up analysis by CIR. Conceivably, this combination can offer better retrospectivity than AICAr concentration alone by allowing to decrease the AICAr concentration threshold without significantly increasing the number of suspicious samples.
Original languageEnglish
JournalDrug testing and analysis
Volume14
Issue number11-12
Pages (from-to)2017-2025
Number of pages9
ISSN1942-7603
DOIs
Publication statusPublished - 12.2022

Bibliographical note

© 2022 John Wiley & Sons Ltd.

ID: 11444962

DOI

View graph of relations